Citadel Advisors’s Ambrx Biopharma Inc AMAM Stock Holding History

Citadel Advisors’s Portfolio AMAM Stock Details AMAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-20,900	Closed	-$298K	–	15758
2023 Q4	$298K	Sell	20,900 -32,600	-61%	-$370K	﹤0.01%	9174
2023 Q3	$615K	Sell	53,500 -7,600	-12%	-$104K	﹤0.01%	7610
2023 Q2	$1.01M	Buy	61,100 +20,800	+52%	+$262K	﹤0.01%	6445
2023 Q1	$359K	Buy	40,300 +28,200	+233%	+$142K	﹤0.01%	8994
2022 Q4	$27.5K	Buy	+12,100	New	+$13.8K	﹤0.01%	12841

Citadel Advisors's AMAM Position: Q1 2024 in Review

Citadel Advisors sold out of Ambrx Biopharma Inc (AMAM) in Q1 2024, closing a stake of 2,042,212 shares — an estimated $29.1M sold.

Citadel Advisors first reported a position in AMAM in Q3 2022 and held it in 6 quarters. The position peaked at $29.1M in Q4 2023. 0 funds tracked by Wall St. Rank hold AMAM as of Q1 2024.

Citadel Advisors reported no remaining Ambrx Biopharma Inc position as of Q1 2024 after selling out during the quarter.
Citadel Advisors sold 2,042,212 Ambrx Biopharma Inc shares in Q1 2024, an estimated $29.1M.
Citadel Advisors first reported a position in Ambrx Biopharma Inc in Q3 2022 and held it in 6 quarters.
Citadel Advisors's Ambrx Biopharma Inc position peaked at $29.1M in Q4 2023.
0 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.